Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2021-002088-23 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mensura EDPB | UNKNOWN |
| Institute of Tropical Medicine, Belgium | OTHER |
| Erasme University Hospital | OTHER |
Not provided
Not provided
Not provided
This is a randomized phase IV dose-optimization study evaluating the safety and immunogenicity of two doses of COVID-19 mRNA vaccines being authorized in the European Union since December 2020: Vaccine BNT162b2 (Comirnaty®; Pfizer-BioNTech) in healthy adults up to age 55 year. Immunogenicity will be measured 28 days after first and second dose, and day 180 and day 365 after first vaccination of 20 and 30 mcg of BNT162b2. The primary outcome is the level of binding antibodies for RBD 28 days after the second dose.
Background: Data from the dose-escalating phase 1 trials from the COVID-19 mRNA vaccines being authorized in the European Union since December 2020, BNT162b2 (Comirnaty®; Pfizer- BioNTech) indicate that for the age group 18-55 years a lower dose of the vaccine can induce the same immune response as the full dose.
Method: This is a randomized multicenter phase IV dose-optimization study evaluating the safety and immunogenicity of demi-doses of a COVID-19 mRNA vaccine being authorized in the European Union since December 2020, BNT162b2 (Comirnaty®; Pfizer- BioNTech) in healthy adults up to age 55 year. The study will be performed in employees of Mensura EDPB at five different sites.
Objectives: The primary outcome is the level of binding antibodies for RBD 28 days after the second dose. Secondary outcomes are safety and reactogenicity after vaccination. The neutralizing antibodies and the cellular immunity 28 days after second dose will be assessed. Humoral and cellular immunity will be measured 180 and 365 days after first dose.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 20 mcg | Experimental | In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 20 mcg. |
|
| Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 30 mcg | Active Comparator | In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 30 mcg. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| immunogenicity after first and second dose | Diagnostic Test | Humoral and cellulair immunity after first and second dose of the different vaccines administrated. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Geometric Mean Titre (GMT) of Binding antibodies to the RBD of SARS-CoV-2 S protein | Binding antibodies anti-RBD | 28 days after second dose |
| Measure | Description | Time Frame |
|---|---|---|
| GMT of Neutralizing anti-bodies to Wuhan strain and variants | 28 days after second dose | |
| T cell response to S protein of Wuhan strain and variants and Memory B cell responses to S protein of Wuhan strain and variants | 28 days after second dose |
Not provided
Inclusion Criteria: Working at Mensura EDPB, not yet vaccinated for COVID19 -
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mensura EDPB | Antwerp | 2000 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42398210 | Derived | Depickere S, Pannus P, Houben S, Charles A, Heyndrickx L, Georges D, Verbrugghe M, Marchant A, Desombere I, Arien KK, Goossens ME. Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial. Vaccine. 2026 Jul 3;89:128897. doi: 10.1016/j.vaccine.2026.128897. Online ahead of print. | |
| 36962838 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
The research nurse administrating the vaccine is the only one who is not blinded.
| Humoral and cellulair immunity | GMT of of Binding antibodies to the RBD of SARS-CoV-2 S protein and Neutralizing anti-bodies to Wuhan strain and variants and T cell response to S protein of Wuhan strain and variants and Memory B cell responses to S protein of Wuhan strain and variants | 180 days after first dose |
| Humoral and cellulair immunity | GMT of of Binding antibodies to the RBD of SARS-CoV-2 S protein and Neutralizing anti-bodies to Wuhan strain and variants and T cell response to S protein of Wuhan strain and variants and Memory B cell responses to S protein of Wuhan strain and variants | 365 days after first dose |
| safety and reactogenicity | adverse events will be followed up after vaccine adminstration | through study completion, an average of 1 year |
| Derived |
| Pannus P, Depickere S, Kemlin D, Houben S, Neven KY, Heyndrickx L, Michiels J, Willems E, De Craeye S, Francotte A, Chaumont F, Olislagers V, Waegemans A, Verbrugghe M, Schmickler MN, Van Gucht S, Dierick K, Marchant A, Desombere I, Arien KK, Goossens ME. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS Glob Public Health. 2022 Dec 20;2(12):e0001308. doi: 10.1371/journal.pgph.0001308. eCollection 2022. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |